Open AccessAdditional possibilities of antihypertensive therapy for metabolic syndrome
Author(s) -
O. A. Kislyak,
Кисляк Оксана Андреевна,
M. V. Pokhilchenko,
Похильченко Мария Викторовна
Publication year - 2013
Publication title -
sistemnye gipertenzii
Language(s) - English
Resource type - Journals
eISSN - 2542-2189
pISSN - 2075-082X
DOI - 10.26442/sg28965
Subject(s) - losartan , metabolic syndrome , medicine , amlodipine , uric acid , abdominal obesity , adiponectin , pharmacology , endocrinology , type 2 diabetes mellitus , diabetes mellitus , candesartan , renin–angiotensin system , insulin resistance , blood pressure
Metabolic syndrome (MS) is a clinical and laboratory symptom complex that encompasses abdominal obesity, carbohydrate and fat metabolic disturbances, arterial hypertension (AH), and target organ involvement. The drugs of first choice in the management of patients with AH and MS are renin-angiotensin-aldosterone system (RAAS) inhibitors, angiotensin receptor blockers (ARB) in particular, when combined with calcium antagonists (CA), which have been proven to be metabolically neutral and able to reduce the risk of type 2 diabetes mellitus. A fixed-dose combination of the ARB losartan and the CA amlodipine has additional capabilities to affect the components of MS due to higher adiponectin and lower uric acid levels.